Embodiments disclosed here are production methods and compositions of engineered immune cells, such as B or T lymphocytes, from limited lineage myeloid progenitor cells, or from pluripotent stem cells, or from multilineage hematopoietic progenitor cells comprising the addition of various cell differentiation transcription factors and inhibiting epigenetic histone methylations in said cells.

The purpose of the present invention is to provide immortalized stem cells, which produce a growth factor capable of regenerating various kinds of tissues that have been damaged by a variety of causes, and a method for producing the aforesaid immortalized stem cells. Another purpose is to provide a medicinal composition and a medicinal preparation for restoring damaged tissues, and a method for the percutaneous absorption of a culture supernatant. Provided are immortalized stem cells that are obtained by isolating stem cells selected from the group consisting of mammalian mesenchymal cells, an embryo at the early stage of the development and somatic cells, first culturing the cells to give first stage culture cells, transferring four kinds of genes into the first stage culture cells to give transgenic cells, and selecting the desired immortalized stem cells from among the transgenic cells using the expression of STRO-1 as an index.

The invention is in the field of cell culturing. More specifically, it is in the field of generating and expanding myogenic cells from induced pluripotent stem (iPS) cells. The invention relates inter alia to cells generated and expanded via such a method, a growth medium specifically suited for the purpose of expanding isolated myogenic cells, and methods for screening compounds on cell structures such as myotubes and myofibers.

The present invention relates to a non-viral iPSCs induction composition and the kits thereof. Specifically, it comprises a recombinant plasmid, and the recombinant plasmid is obtained by constructing the DNA sequences expressing the reprogramming factors POU5F1, SOX2, GLIS1, KLF4, MYCL and hsa-miR-302s into an episomal vector; The DNA sequence of hsa-miR-302s comprises one or more sequences selected from hsa-miR-302a, hsa-miR-302b, hsa-miR-302c and hsa-miR-302d. The induction composition is suitable for a highly safe and non-integrated induction reprogramming to obtain iPSCs, which reduces the risk of the clinical applications without an introduction of the high-risk reprogramming factors such as c-MYC, SV40-LT and TP53 inhibitors.

The present invention relates to a non-viral iPSCs induction method as well as the compositions, kits and iPSCs obtained therefrom. More specifically, the induction method comprises the following steps: 1) Constructing a recombinant plasmid by introducing the DNA sequences expressing the reprogramming factors POU5F1, SOX2, GLIS1, KLF4, MYCL and hsa-miR-302s into an episomal vector; 2) Obtaining iPSCs by introducing the recombinant plasmids obtained in step 1) into human somatic cells, and reprogramming induction culture of the cells. The method reduces the risk of clinical applications of iPSCs by using a combination of highly-safe reprogramming factors without the introduction of high-risk reprogramming factors such as c-MYC, SV40-LT and TP53 inhibitors; The method is highly applicable.

Provided herein are systems and methods for identifying cell-specific differentiation markers. In particular, provided herein are systems and methods for generating induced pluripotent cells (IPS) from human cells, differentiating the IPS into differentiated cells, and identifying differentiation specific markers.

The disclosure provides an episome comprising OCT4, KLF4, SOX2, cMYC, NANOG, LIN28, and NRSA2. Also disclosed is a method for producing an induced pluripotent stem (iPS) cell. The method comprises introducing an episome into a cell, wherein the episome comprises OCT4, KLF4, SOX2, cMYC, NANOG, LIN28, and NRSA2, and growing the cell under conditions to select for the presence of the episome. The method also comprises selecting a primary clone and growing the primary clone in a medium comprising a MEK inhibitor and a GSK3b inhibitor.

This document provides methods and materials involved obtaining induced pluripotent stem (iPS) cells. For example, methods and materials for increasing the efficiency for making iPS cells as well as methods and materials for selecting iPS cells are provided.

A recombinant vector for producing an induced pluripotent stem cell, including an Oct family gene, a Klf family gene, and a Myc family gene, wherein the genes are inserted in the vector and an induced pluripotent stem cell including the recombinant vector. Also disclosed is a method for preparing a recombinant vector for producing an induced pluripotent stem cell, including inserting each of the three genes into a vector such that the genes are capable of expression. Also disclosed are a first recombinant vector for preparing a second recombinant vector for producing an induced pluripotent stem cell, said first recombinant vector including at least two of the following four genes: an Oct family gene, a Klf family gene, a Myc family gene and a Sox family gene. Also disclosed is a method for preparing the first recombinant vector, including inserting the at least two genes into a vector.

Provided is a method for inducing a skeletal muscle cell including a step of introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into a somatic cell of a mammal.